Other languages Bristol-Myers Squibb Company Swiss Exchange

Equities

BMY

US1101221083

Market Closed - Swiss Exchange Other stock markets 11:35:20 2019-06-28 am EDT			5-day change	1st Jan Change
44.39 ^CHF	-0.25%		-18.16%	-18.16%

Jul. 12	UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating	MT
Jul. 11	Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	Jul. 02
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	Jul. 01
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin	Jul. 01
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	Jun. 27
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	Jun. 26
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	Jun. 26
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	Jun. 26
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	Jun. 26
Bristol Myers : approbation accélérée en cancer colorectal	Jun. 24
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	Jun. 21
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	Jun. 21
US FDA approves Bristol Myers' colorectal cancer therapy	Jun. 21
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	Jun. 21
Bristol Myers : demande validée pour Opdivo sous-cutané	Jun. 21
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	Jun. 21
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey	Jun. 20
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	Jun. 19
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	Jun. 18
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	Jun. 18
Bristol Myers : dividendes décidés par le conseil	Jun. 18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST